MiMedx Group Inc. (NASDAQ:MDXG)’s share price shot up 3.4% during trading on Monday . The stock traded as high as $7.60 and last traded at $7.55, with a volume of 514,754 shares changing hands. The stock had previously closed at $7.30.

Several research firms recently commented on MDXG. Brean Capital reaffirmed a “buy” rating on shares of MiMedx Group in a report on Wednesday, June 29th. Zacks Investment Research raised shares of MiMedx Group from a “sell” rating to a “hold” rating in a report on Wednesday, June 29th. Finally, First Analysis lowered shares of MiMedx Group from an “overweight” rating to an “equal weight” rating and reduced their target price for the company from $14.00 to $9.00 in a report on Wednesday, April 27th. Three investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $10.89.

The stock has a market capitalization of $818.16 million and a price-to-earnings ratio of 35.237. The firm’s 50 day moving average is $7.68 and its 200 day moving average is $7.89.

MiMedx Group (NASDAQ:MDXG) last released its earnings results on Tuesday, July 26th. The company reported $0.05 EPS for the quarter, missing the consensus estimate of $0.07 by $0.02. The firm had revenue of $57 million for the quarter, compared to analysts’ expectations of $56.49 million. The business’s quarterly revenue was up 25.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.05 earnings per share. Equities analysts expect that MiMedx Group Inc. will post $0.23 earnings per share for the current fiscal year.

In other news, insider William Charles Taylor sold 29,112 shares of the business’s stock in a transaction on Monday, August 1st. The shares were sold at an average price of $7.55, for a total value of $219,795.60. Following the transaction, the insider now owns 612,316 shares of the company’s stock, valued at $4,622,985.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

An institutional investor recently raised its position in MiMedx Group stock. Wells Fargo & Company MN increased its stake in MiMedx Group Inc. (NASDAQ:MDXG) by 19.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,041,546 shares of the company’s stock after buying an additional 169,102 shares during the period. Wells Fargo & Company MN owned about 0.96% of MiMedx Group worth $9,759,000 as of its most recent SEC filing.

MiMedx Group, Inc (MiMedx) is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues and human skin and bone. The Company operates in the Regenerative Biomaterials business segment, which includes the development, processing and marketing of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues in the wound care, surgical, sports medicine, ophthalmic and dental market categories.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.